All Family Resources
All Clinician Resources

Update on a Promising New Drug to Treat JM: Vamorolone

Cure JM is making extraordinary progress in juvenile myositis (JM) research, including a partnership with ReveraGen Biotech to advance the drug vamorolone toward a clinical trial in JM.

Vamorolone is a steroid replacement with all the benefits of steroid treatment without devastating side effects. Vamorolone is currently in a clinical trial in Duchenne Muscular Dystrophy children.

Findings so far indicate improved safety relative to prednisone. Cure JM is working with vamorolone’s sponsor, ReveraGen, to design a clinical trial to test the drug’s safety in JM children. ReveraGen’s VP of Research, Eric Hoffmann, Ph.D., gives us an update on vamorolone and the status of a clinical trial in JM.

Balancing Work and Caregiving: Strategies for Working Parents of Children with Juvenile Myositis

Balancing Work and Caregiving: Strategies for Working Parents of Children with Juvenile Myositis

Balancing the demands of a career with the responsibilities of caregiving is a challenging task for any parent. For those with a child diagnosed with juvenile myositis (JM), a rare autoimmune disease affecting children, the challenge is heightened. Juggling work commitments while providing the necessary care and support for a child with JM can be taxing. In this article, we hope to provide you with a few effective strategies and insights to help working parents navigate this delicate balance.

Nathanael’s Story

Nathanael was an active 7-year-old. In the summer of 2014, he played baseball under the Southern California sun, and that’s when the rash started. “He

Join Cure JM

Membership is free and we’ll connect you with a network of support, encouragement, and resources.

Join Now
Cure JM supports families, patients, and the juvenile myositis research community.

Interested in DIY fundraising but need help?

We’re here to help!

To have your fundraiser matched, add “DIY Match” in the memo of your online gift or check.